Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of UA007 in Acute Gouty Arthritis
ChiCTR2200062847Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UA007 in gout, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Change in patient-assessed pain intensity in index joint from baseline to 72 hours. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
UA007
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR2200062847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062847.